Product Description
GW1929 is a potent PPAR-γ activator, with pKis of 8.84, < 5.5, and < 6.5 for human PPAR-γ, PPAR-α, and PPAR-δ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively.
IC50 & Target: pKi: 8.84 (Human PPAR-γ), < 5.5 (Human PPAR-α), < 6.5 (Human PPAR-δ)[1]
pEC50: 8.56 (Human PPAR-γ), 8.27 (Murine PPAR-γ)[1]
In Vitro: GW1929 is a potent PPAR-γ activator, with pKis of 8.84, < 5.5, and < 6.5 for human PPAR-γ, PPAR-α, and PPAR-δ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively[1]. GW1929 (10 μM) inhibits TBBPA-induced caspase-3 increase and TBBPA-stimulated LDH release in neocortical cell cultures[2].
In Vivo: GW1929 (0.5, 1, 5 mg/kg, p.o.) highly decreases nonfasted plasma glucose levels in Zucker diabetic fatty (ZDF) rats after treatment for 14 days, and possesses antilipolytic efficacy. GW1929 (1, 5 mg/kg, p.o.) increases glucose-stimulated insulin secretion of β-cell in ZDF rats[1].
Information
CAS No196808-24-9
FormulaC30H29N3O4
Clinical Informationclinicalinformation
PathwayCell Cycle/DNA Damage
TargetPPAR